சமூகம் ஆஃப் சிறுநீரக புற்றுநோயியல் ஆண்டு சந்தித்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சமூகம் ஆஃப் சிறுநீரக புற்றுநோயியல் ஆண்டு சந்தித்தல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சமூகம் ஆஃப் சிறுநீரக புற்றுநோயியல் ஆண்டு சந்தித்தல் Today - Breaking & Trending Today

SUO 2020: The Role of Prostate-Specific Membrane Antigen (PSMA) Scanning in Prostate Cancer (Up)Staging

SUO 2020: The Role of Prostate-Specific Membrane Antigen (PSMA) Scanning in Prostate Cancer (Up)Staging
(UroToday.com) At the 2020 virtual Society of Urologic Oncology s (SUO) prostate cancer session, Dr. Declan Murphy discussed the role of prostate-specific membrane antigen (PSMA) scanning in prostate cancer staging. Dr. Declan Murphy states that PSMA PET/CT is an obvious challenger to conventional imaging.
Because there was a lot of retrospective data (particularly in Australia) with PSMA PET-CT, Dr. Murphy and colleagues set out to assess prospectively the use of PSMA PET-CT among patients with high-risk prostate cancer before curative-intent surgery or radiotherapy – the proPSMA study. ....

United States , Zachary Klaassen , Declan Murphy , Peter Maccallum Cancer Centre , Society Of Urologic Oncology Annual Meeting , Society Of Urologic Oncology , Augusta University Medical College Of Georgia , Outcomes Research , Georgia Cancer Center , Australian Prostate Cancer Research Centre , Urologic Oncology , Royal Melbourne Hospital , Australian Prostate Cancer Research , Assistant Professor , Medical College , Urologic Oncology Annual Meeting , ஒன்றுபட்டது மாநிலங்களில் , சக்கரி க்லாஸ்சேங் , டெக்லான் மர்பி , பீட்டர் மக்காலம் புற்றுநோய் மையம் , சமூகம் ஆஃப் சிறுநீரக புற்றுநோயியல் ஆண்டு சந்தித்தல் , சமூகம் ஆஃப் சிறுநீரக புற்றுநோயியல் , அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா , ஔட்கம்ஸ் ஆராய்ச்சி , ஜார்ஜியா புற்றுநோய் மையம் , ஆஸ்திரேலிய ப்ராஸ்டேட் புற்றுநோய் ஆராய்ச்சி மையம் ,

SUO 2020: Results from the PROfound Study, A New Second Line Therapy for mCRPC

SUO 2020: Results from the PROfound Study, A New Second Line Therapy for mCRPC
(UroToday.com) In the second Prostate Cancer session at this year’s Society of Urologic Oncology virtual annual meeting, Dr. Maha Hussain discussed the role of poly ADP ribose polymerase (PARP) inhibitors, particularly olaparib, in metastatic castration-resistant prostate cancer.
Dr. Hussain began by reviewing the rationale for targeting PARP-1 in advanced prostate cancer given its implicated role in many aspects of prostate cancer including its role in mediating DNA repair response to alkylating agents, in cellular survival in BRCA deficient cells, and in androgen-receptor mediated prostate cancer cellular proliferation. Further, the Stand Up To Cancer (SU2C) project analysis demonstrated that more than 20% of patients with mCRPC harbor DNA repair pathway aberrations including BRCA2, BRCA1, ATM and many others of which 8-10% are pathogenic germline findings. ....

United States , Foundationone Cdx , Christopher Jd Wallis , Maha Ha Hussain , Maha Hussain , Olaparib Lynparza , Society Of Urologic Oncology Annual Meeting , Society Of Urologic Oncology , Drug Administration , Northwestern University Feinberg School Of Medicine , Department Of Medicine , Division Of Hematology , Prostate Cancer , Urologic Oncology , Stand Up To Cancer , Versus Enzalutamide , Abiraterone Acetate , New England Journal , Homologous Recombination Gene Deficiency , Federal Drug Administration , Genevieve Teuton Professor , Northwestern University Feinberg School , Urologic Oncology Annual Meeting , ஒன்றுபட்டது மாநிலங்களில் , கிறிஸ்டோபர் ஜ்ட் வாலிஸ் , மஹா எச்ஏ ஹுசைன் ,

SUO 2020: Impact of PSMA Scans on Clinical Management-Point/Counterpoint

SUO 2020: Impact of PSMA Scans on Clinical Management-Point/Counterpoint
(UroToday.com) To conclude the advances in prostate cancer session Drs. Matthew Cooperberg and Tanya Dorff debated whether prostate-specific membrane antigen (PSMA) imaging should be routinely used in the clinical management of prostate cancer.
Earlier this week the Food and Drug Administration (FDA) approved Gallium 68 PSMA-11 as the first prostate membrane specific antigen based tracer for PET CT imaging. The tracer was specifically approved to aid in the detection of metastatic prostate cancer. Despite the approval, guidelines have yet to clarify the role of PSMA versus conventional imaging.
Dr. Cooperberg began the session by providing the argument against the widespread adoption of PSMA-PET imaging into our current prostate cancer algorithms. He acknowledged the abundance of literature demonstrating superior detection rates with PSMA-PET over conventional imaging, even in the setting of ....

United States , Fox Chase Cancer Center , San Francisco , Tanyab Dorff , Matthew Cooperberg , Matthewr Cooperberg , Tanya Dorff , Adrien Bernstein , University Of California , Society Of Urologic Oncology , Society Of Urologic Oncology Annual Meeting , Drug Administration , Department Of Medical Oncology Therapeutics Research , Helen Diller Family Chair , Associate Clinical Professor , Medical Oncology , Therapeutics Research , Urologic Oncology Fellow , Urologic Oncology Annual Meeting , ஒன்றுபட்டது மாநிலங்களில் , நரி துரத்து புற்றுநோய் மையம் , சான் பிரான்சிஸ்கோ , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா , சமூகம் ஆஃப் சிறுநீரக புற்றுநோயியல் , சமூகம் ஆஃப் சிறுநீரக புற்றுநோயியல் ஆண்டு சந்தித்தல் , துறை ஆஃப் மருத்துவ புற்றுநோயியல் சிகிச்சை ஆராய்ச்சி ,

SUO 2020: Debate: Relugolix for Advanced Prostate Cancer is the New Standard (The HERO Study)

SUO 2020: Debate: Relugolix for Advanced Prostate Cancer is the New Standard (The HERO Study)
(UroToday.com) During the second prostate cancer session at the 2020 Annual Meeting of the Society of Urologic Oncology (SUO), Drs. Neal Shore and Ashley Evan Ross debated the use of relugolix as a new standard of care for androgen deprivation therapy (ADT) for the treatment of prostate cancer.
This debate follows the publication of the HERO trial,
1
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO), which was published in the New England Journal of Medicine in June 2020 and of which Dr. Shore is the lead author. This was a randomized controlled comparing relugolix, an oral gonadotropin-releasing hormone antagonist, to leuprolide. 120mg relugolix was given by mouth daily and leuprolide was given every 3 months as depot injections. The primary end point was “sustained castration”, meaning a testosterone level ....

United States , Fox Chase Cancer Center , Marshall Strother , Ashley Ross , Ashley Evan Ross , Society Of Urologic Oncology Annual Meeting , Carolina Urologic Research Center , Division Of Urologic Oncology , Meeting Of The Society Urologic Oncology , United States Federal Drug Administration , Northwestern Medical Group , Health Drug , Feinberg School Of Medicine , Society For Urologic Oncology , Urologic Oncology , Neal Shore , Men With Advanced Prostate Cancer , New England Journal , Medical Director , Carolina Urologic Research , Associate Professor , Feinberg School , Northwestern Medical , Urologic Oncology Fellow , Urologic Oncology Annual Meeting , Treatment Patterns ,

SUO 2020: Optimizing Management of High Risk Non-Muscle-Invasive Bladder Cancer – Case Based Discussion

SUO 2020: Optimizing Management of High Risk Non-Muscle-Invasive Bladder Cancer – Case Based Discussion
(UroToday.com) The plenary session of the last day of the 2020 Annual Meeting of the Society of Urologic Oncology (SUO) began with a panel discussion stepping through the case of a patient with non-muscle invasive bladder cancer.
Dr. Sima Porten, the moderator, introduced the case: a 60-year-old otherwise healthy male with high-volume high-grade Ta urothelial carcinoma of the bladder diagnosed on an initial transurethral resection (TUR) with no muscle in the initial specimen.
The panel first addressed the question of perioperative chemotherapy for this patient. There was immediate resounding consensus that, based on the results of SWOG S0337 ....

University Of Washington Medical Center , United States , Fox Chase Cancer Center , University Of Missouri , Sumeet Bhanvadia , Sarah Psutka , Marshall Strother , Sima Porten , Sarahp Psutka , Sumeet Kaur Bhanvadia , Janet Baack Kukreja , Katies Murray , Janet Kukreja , Urological Oncology At Ellis Fischel Cancer Center , Society Of Urologic Oncology Annual Meeting , Missouri University Of , University Of Southern California , Professor For The Department Of Urology , Meeting Of The Society Urologic Oncology , Urology Division , United States Federal Drug Administration , University Of California San Francisco , Society For Urologic Oncology , University Of Colorado Denver , Keck School Of Medicine , Division Of Urologic Oncology ,